DNAH8 and metabolic dysfunction-associated steatotic liver disease: Recent studies reported that ATPase inhibitors are closely related to fatty oxidation and liver fibrosis (Cortez-Pinto et al., 1999; Orlov et al., 2019), which are the pathological basis of NAFLD development.